Literature DB >> 33889861

Retrospective observational RT-PCR analyses on 688 babies born to 843 SARS-CoV-2 positive mothers, placental analyses and diagnostic analyses limitations suggest vertical transmission is possible.

G Bahadur1,2, M Bhat3, S Acharya3, D Janga1, B Cambell1, J Huirne4, W Yoong1, A Govind1, J Pardo1, R Homburg2.   

Abstract

RESEARCH QUESTION: Is there vertical transmission (from mother to baby antenatally or intrapartum) after SARS-CoV-2 (COVID-19) infected pregnancy? STUDY
DESIGN: A systematic search related to SARS-CoV-2 (COVID-19), pregnancy, neonatal complications, viral and vertical transmission. The duration was from December 2019 to May 2020.
RESULTS: A total of 84 studies with 862 COVID positive women were included. Two studies had ongoing pregnancies while 82 studies included 705 babies, 1 miscarriage and 1 medical termination of pregnancy (MTOP). Most publications (50/84, 59.5%), reported small numbers (<5) of positive babies. From 75 studies, 18 babies were COVID-19 positive. The first reverse transcription polymerase chain reaction (RT-PCR) diagnostic test was done in 449 babies and 2 losses, 2nd RT-PCR was done in 82 babies, IgM tests were done in 28 babies, and IgG tests were done in 28 babies. On the first RT-PCR, 47 studies reported time of testing while 28 studies did not. Positive results in the first RT-PCR were seen in 14 babies. Earliest tested at birth and the average time of the result was 22 hours. Three babies with negative first RT-PCR became positive on the second RT-PCR at day 6, day 7 and at 24 hours which continued to be positive at 1 week.Four studies with a total of 4 placental swabs were positive demonstrating SARS-CoV-2 localised in the placenta. In 2 studies, 10 tests for amniotic fluid were positive for SARS-CoV-2. These 2 babies were found to be positive on RT-PCR on serial testing.
CONCLUSION: Diagnostic testing combined with incubation period and placental pathology indicate a strong likelihood that intrapartum vertical transmission of SARS-CoV-2 (COVID-19) from mother to baby is possible.
Copyright © 2021 Facts, Views & Vision.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; pregnancy; risks; vertical transmission

Year:  2021        PMID: 33889861      PMCID: PMC8051196          DOI: 10.52054/FVVO.13.1.001

Source DB:  PubMed          Journal:  Facts Views Vis Obgyn        ISSN: 2032-0418


Introduction

In the current SARS-CoV-2 (COVID-19) pandemic, testing has become a cornerstone for public health advice, policies and political agenda. The unprecedented and exponential growth of non-peer- reviewed publications, systematic reviews lacking rigorous thoroughness and the repetitive inclusion of case reports is problematic (Bauchner, 2020). We critically appraised the limitations and manner of diagnostic testing in obstetric medicine (Bahadur et al., 2020). While the genetic sequence for SARS- CoV-2 became available (Wang et al., 2020), it was only after mid-April 2020 that profound concerns were aired about the very high false-negative rates for antibodies. This false-negative rate for antibodies has come down from almost 1 in 2 to 1 in 3 tests, possibly because the reverse transcription polymerase chain reaction (RT-PCR) tests were based on the previous SARS family virus (Bahadur et al., 2020). The second major limitation is the fact that most researchers had not taken account of the incubation period, which for SARS-CoV-2 is 5-6 days (Li Q et al., 2020) and most publications have relied on a single test rather than serial checks, thereby producing scientifically unreliable conclusions. There is also the possibility that latent infections exist even before the onset of symptoms (Anderson et al., 2020) and the earliest trigger for transmission occurs before the onset of symptoms which could be one to two days if with viraemia (Zou et al., 2020). The safety margins to assess the likelihood of infection before the onset of infection should be revised towards 7-8 days, which is different from the World Health Organisation (WHO) RT-PCR testing recommendation for the asymptomatic or mildly symptomatic (WHO, 2020). Asymptomatic carriers acquiring and transmitting SARS-CoV-2 remains an underexplored area (Bai et al., 2020) against those cases with confirmed SARS- CoV-2 clinical symptoms (Huang et al., 2020). Serological testing is a measure of a by-gone event (WHO, 2020) with probable clues on the long-term immunity or immunological memory and route to immunisation (Dijkstra et al., 2020). IgM provides the initial defence to viral infections, before generating the adaptive IgG response. From 173 SARS-CoV-2 infected patients and 535 plasma samples, the median seroconversion time for total antibody (Ab), IgM and then IgG was day 11, day 12 and day 14, respectively. The antibodies were present in <40% among patients within 1-week of onset, and rapidly increased to 100 % (Ab), 94.3% (IgM) and 79.8% (IgG) 15 days after onset (Jacofsky et al., 2020; Li Z et al., 2020). Furthermore, cross-reactivity against multiple coronavirus strains with similar antigen sites can become problematic (Jacofsky et al., 2020; Xiao et al., 2020). This retrospective observational study on RT-PCR analyses on babies born to SARS-CoV-2 positive mothers sets out to analyse how SARS-CoV-2 diagnostic analyses and placental analyses were performed, their scientific limitations in interpreting data and whether intrapartum vertical transmission from mother to baby was possible.

Methods

Study design, size, duration

A systematic review searching terms related to SARS-CoV-2, COVID-19, pregnancy, neonatal complications, viral and vertical transmission was conducted. No language restriction was placed on published articles. The duration was from 1st December 2019 to 15th May 2020 for extracting the literature and screening the articles of potential interest.

Participants/materials, setting, methods

A systematic review following the PRISMA format was performed in PUBMED, EMBASE, CENTRAL, WEB of SCIENCE, Web of Knowledge, the WHO, RCOG, ESHRE, ASRM, NEJM, BMJ, Lancet, Welcome and Cochrane Central Register of Studies, UKOSS, Office of National Statistics (ONS-UK), Department of Health (UK), Google Scholar and any references of relevant articles. Data relevant to SARS-CoV-2 diagnostic interpretation was also collected. Case reports or case series of pregnant women with confirmed COVID-19, where neonatal outcomes were reported were assembled on an Excel spreadsheet.

Results

A total of 84 studies with 862 COVID-19 positives were included. Two studies had ongoing pregnancies while the remaining 82 studies included 705 babies, one miscarriage and one medical termination of pregnancy (MTOP). Of the 84 studies, 1st RT-PCR was undertaken in 449 babies and two losses in 75 studies. Seven studies did not report testing, while two had ongoing pregnancies. Forty-one studies had only one RT- PCR testing done. 34 studies had a 2nd RT-PCR done. Overall excluding two losses, there were 431 negative, 14 positive and four unclear results (total=449) in the 1st RT-PCR. 356/431(82.5%) babies had only one negative RT-PCR (no serial testing). The time at which 1st RT-PCR was done was recorded in 47 studies (165/449 babies) but not in 28 studies (284/449 babies). Considering the 47 studies with 165 babies, the mean times of negative and positive results were 28 hours (day 1 after birth, day 1) and 22 hours (day of birth, day 0) respectively. 2nd RT-PCR was reported in 34 studies and 82 babies. 74 were negative and eight were positive. The mean time of negative result was 92 hours / day 4 (Figure 1).
Figure 1

— 1st and 2nd RT PCR testing in babies born to COVID 19 positive mothers.

— 1st and 2nd RT PCR testing in babies born to COVID 19 positive mothers. Positive results in 1st RT-PCR were documented in 14 babies. The earliest were tested at birth and the average time of the result was 22 hours/ day 0. Three babies with negative 1st RT-PCR became positive in 2nd RT-PCR at D6, D7 and at 24 hours which continued to test positive at 1 week. One baby with an equivocal result with 1st RT-PCR became positive in subsequent testing on day 3 (Figure 1, Table 1).
Table I

RT-PCR results in babies tested positive.

StudyNo. of babies tested/total no. of babies in the study1st RT-PCRTime at which 1st RT-PCR done2nd RT-PCRTime at which 2nd RT-PCR done3rd and subsequent RT-PCRTime at which test done
Yu N et al3/71 positive36 hours1 negativewithin 2 weeks1 negative Within 2 weeks
Zeng L et al33/333 positiveDay 2 & 43 negative2 on Day 6 & 1 on day 7  
Wang S et al1/11 positive36 hours1 negativeDay 15  
Ferrazzi E et al42/422 positive1 doubtfulDay 12 positive1 positiveDay 3  
Alzamora MC et al1/11 positive16 hrs1 positive48 hrs  
Khan S et al17/172 positive24 hrsNot tested   
Nie R et al26/281 positive36 hrs1 negativeDay 41 negativeDay 8 & 15
Carosso A et al1/11 positive0 hr1 negative37 hrs  
Hu X et al7/71 positive36 hrNot tested   
Diaz SA et al1/11 negativeDay 61 positiveDay 81 positiveDay 13
Zamaniyan M et al1/11 negative0 hr1 positive24 hrs1 positive1 week
Hantoushzadeh S et al5/95 negativeDay 11 positiveDay 7  
Kirtsman M et al1/11 positiveAt birth1 positiveDay 21 positiveDay 3

This table includes all babies who were positive on RT-PCR at some point. Out of the 18 babies who were positive at some point, only 3 have positive result after 5 days of life. These 3 babies had initial negative result. All the rest had positive result within first 5 days and either became negative or were not tested further or continued to have positive result but these were within first 5 days.

RT-PCR results in babies tested positive. This table includes all babies who were positive on RT-PCR at some point. Out of the 18 babies who were positive at some point, only 3 have positive result after 5 days of life. These 3 babies had initial negative result. All the rest had positive result within first 5 days and either became negative or were not tested further or continued to have positive result but these were within first 5 days. Antibody testing (IgM/IgG) was done in 28 babies from six studies. Twenty-one babies had negative results, while 7 (25%) were positive (3 had positive IgM and all 7 had positive IgG). All three babies with positive IgM had negative RT-PCR. IgG could be acquired by transfer from mum through the placenta. All except one baby with positive IgG had a positive 1st RT-PCR. When this same swab was repeated after 37 hours, RT-PCR was negative. In the two studies where babies were positive for IgM, no information was available on placental swabs, cord blood or amniotic fluid. One baby with negative antibody testing had positive 1st RT-PCR at 16 hrs after birth and the mother became antibody positive on postpartum day 4. In order to confirm vertical transmission, amniotic fluid, and placenta and cord blood were assessed for evidence of infection with SARS-CoV-2 by RT-PCR results. In 15 studies (46 women) had sent placental swabs. Four studies with a total of four placental swabs were positive. Positive placental swabs on histology demonstrated SARS-CoV-2 localised predominantly to the syncytiotrophoblast cells of the placenta. In 17 studies, amniotic fluid from 67 women was tested for COVID-19. In two studies, 10 tests were positive. In these, two babies were found to be positive on RT-PCR on serial testing. Cord blood samples were tested in 77 cases (in 15 studies) and all except one was negative. This particular study included one woman who had a MTOP for maternal compromise with severe pre- eclampsia and COVID-19 infection with possible placental abruption. Fetal heart and lung tissues tested negative for SARS-CoV-2, whilst placenta and cord blood were found to be positive. Out of the 705 babies and 2 non-viable fetuses, 18 babies were found to be positive on at least one RT-PCR testing. Timing and serial testing were done in 82 babies (>= 2 tests).

Discussion

Pregnant women are considered to be a high-risk group for SARS-CoV-2 infection, with potentially adverse maternal and perinatal outcomes, with an increased risk of admission to an intensive care unit (ICU) (Allotey et al., 2020). There was an increased likelihood of admission to the ICU (odds ratio (OR) 1.62, 95% CI 1.33 - 1.96) and requiring invasive ventilation (OR 1.88, 95% CI 1.36 -2.60) among pregnant women compared to non-pregnant women with COVID-19. Confirmed SARS-CoV-2 positive patients had a higher risk of delivering preterm and infants born to these mothers were more likely to be admitted to the neonatal intensive care unit. A quarter of all neonates from positive mothers were admitted to ICU. There appeared to be a 7% positivity rate among women universally screened for COVID-19 during pregnancy (Allotey et al., 2020). The rates of spontaneous and overall preterm birth were 6% and 17% respectively, while of the 11,000 pregnant women with SARS-CoV-2, 73 died (Allotey et al., 2020). Of 598 hospitalised pregnant women with SARS-Cov-2, about 55% were asymptomatic (Delahoy et al., 2020). Vertical transmission and congenital abnormalities experienced with Zika virus raise concerns about SARS-Cov-V-2 (Krauer et al., 2017; Hintley et al., 2020). Maternal characteristics. Hypothyroidism and advanced maternal age were a common maternal morbidity. Elderly mums. For babies with positive results after D5 – 2 mums were critically ill and died after delivery. xNR- Not recorded. If more than half of SARS-CoV-2 infected pregnant women were asymptomatic there are healthcare implications in managing all patients and staff within a clinical setting (Delahoy et al., 2020). Equally the meaningfulness of the SARS-CoV-2 diagnostic analyses needs to be addressed against the backdrop of high levels of false negatives results relying on a single test which would thereby not inform us a true value of SARS-CoV-2 vertical transmission (Woloshin et al., 2020). Our data and interpretation suggest the need to improve our understanding when testing has to be performed and when to repeat to reach a meaningful clinical decision process and especially where validation of test had not occurred, the sensitivity not reported and where gold standard and controls remained obscure. What is now known is that there can be 100% false negatives on the first day of showing symptoms from an infected individual and dropping to 67% on day 4. Thus, the validity of the RT-PCR post symptoms would only be valid from days 5 to 12 after which RT-PCR becomes negative (Kucirka et al., 2020). In four cohorts, 100% of patients initially tested negative but turned positive after 2nd and 3rd re-tests for SARS-CoV-2 RNA (Kelly et al., 2020). False-negative testing for SARS-CoV-2 is a serious clinically relevant problem and this should be overcome by serial testing in the 5-7 days incubation period post-infection (Kelly et al., 2020). In our study cohort there is no evidence that any of the researchers have been aware of the relevance of timing of testing or the need for serial testing to ensure the repeatability of an initial negative result thereby leading to inappropriate reassurances and conclusions about the health and status of SARS- CoV-2 infected mothers and babies with all its implications for healthcare workers in attendance. The most striking feature from our data analyses of 84 studies was the over-reliance on a single RT- PCR negative test in 41 papers and the absence of documentation of time that the sample were taken in 28 papers (Figure 1). Given the incubation period, a single result cannot be used meaningfully, and conclusions remain unsupported by the available evidence. In 82.5% babies, only 1 negative RT- PCR done on an average on day 1 was relied upon. Even in babies having had 2nd negative RT-PCR, the test was done within 96 hours/ day 4. Based upon the understanding that the incubation period is > 5 days, the validity of this testing is questionable. In the few sequential tests performed these appeared more random rather than scientific reasoning in relation to the incubation period for SARS-CoV-2 viral infection. Antibody testing has very limited value in unravelling the status of vertical transmission. IgG molecules can travel across the placental membranes; hence its’ presence does not support or refute vertical transmission. In two studies involving babies having positive IgM, there was no other supporting information supporting vertical transmission. In addition, RT-PCR in these babies was negative. From our analyses there remains sparse and meaningless information of the time for the production of IgM and IgG along with limited publication and possibly antibodies are more significant for long term immunity. The strength of our study was the analysis of a substantial data set of publications and the manner in which the diagnostic tests were performed, revealing poor interpretation and meaningful follow up. Given the diagnostic tests were developed on the SARS Middle Eastern strain and in the period of study, the validation of these tests had not been established or undertaken and this adds to the weaknesses over which we do not have control. Little information existed in the validation of diagnostic tests being utilised. Numerous tests have come onto the market since these studies were reported with differing sensitivities and specificities (Corman et al., 2020; Bahadur et al., 2020; Laureano and Riboldi, 2020) and its use to derive reassurances on major healthcare implication for mothers, babies and healthcare workers need caution. Single occasion screening is likely to miss potentially infected people (Viswanathan et al., 2020) and clinicians should not rely on unexpected negative results and performing serial tests could overcome an individual test’s limited sensitivity. Recent studies though not covered in our analyses are unlikely to alter the findings of this study as concerns about the lack of serial diagnostic analyses remain. As far as we can ascertain this risk is minimal in our cohort analyses and our study remains robust and contributes to the growing body of information on maternal-fetal effect during the SARS-CoV-2 pandemic. Vertical transmission from mother to baby is rare and when this occurs there are serious health implications for the baby. The SARS-CoV-2 studies included in our cohort do cover placental pathology reports (Hosier et al., 2020, Kirstman et al., 2020, Schoenmakers et al., 2020, Shanes et al., 2020). The histological analyses in these reports point to a strong indication that intrapartum vertical transmission from mother to fetus had occurred (Table VIII). Our data also highlight the need to look at vertical transmission alongside placental pathologies where SARS-CoV-2 invasion of the placenta shows the potential for severe morbidity in pregnant women (Hosier et al., 2020). Another likely case of vertical transmission indicates neonates should have SARS-CoV-2 testing of the nasopharynx, placenta and cord blood as soon as possible after birth, while sample timing and collection methods should be documented (Kirtsman et al., 2020). There is limited information on how long the women were positive for SARS Cov2 virus and how soon transplacental transmission occurs. Assuming babies acquired infection in utero nearer delivery, it would be expected that the babies would be positive after the incubation period, most likely in the five days following delivery. In our review, there were only two babies who were negative soon after delivery but became positive five days later and one who became positive at 24 hours and continued to be positive at one week. All the other babies had positive RT-PCR within five days of birth. Of these three babies, two had positive amniotic fluid raising the possibility of vertical transmission (Table VI). Had it been contamination from amniotic fluid, RT- PCR would be expected to be positive in the initial testing soon after birth (Table VII).
Table VIII

Placental histology.

StudyNo. of womenNo. of babiesPlacental histology
Schoenmakers S et al11 negativePlacenta showed the presence of SARS-CoV-2 particles with generalized inflammation characterized by histiocytic intervillositis with diffuse perivillous fibrin depositions with damage to the syncytiotrophoblasts.The maternal side of the placenta had a viral load of 4.42 log copies /mL, while the fetal side had 7.15 log copies /mL.
Hosier H et al1MTOP-negativeThe placenta was remarkable for the presence of diffuse perivillous fibrin and an inflammatory infiltrate composed of macrophages as well as T lymphocytes, consistent with histiocytic intervillositis. SARS–CoV-2 localized predominantly to the syncytiotrophoblast cells of the placenta.
Shanes ED1615 babies negative1 miscarriage- not testedPlacentas show increased prevalence of decidual arteriopathy and other features of maternal vascular malperfusion, a pattern of placental injury reflecting abnormalities in oxygenation within the intervillous space associated with adverse perinatal outcomes.
Kirtsman M et al11 positivePlacenta showed multiple areas of infiltration by inflammatory cells and extensive early infarction, largely confined to the intervillous space, consistent with chronic histiocytic intervillositis. There was extensive early necrosis of the syncytiotrophoblast layer.

*MTOP- Medical termination of pregnancy

Table VI

Placenta, amniotic fluid, cord blood, breast milk, vaginal swab results.

StudyPlacentaAmniotic fluidCord bloodVaginaBreast milk
Yu N et alNegative Negative  
Zeng L et al NegativeNegative Negative
  NegativeNegative Negative
  NegativeNegative Negative
Wang S et alNegative Negative Negative
Ferrazzi E et al     
      
Alzamora MC et al     
Khan S et al     
Nie R et alNegative negative  
Carosso A et alfetal and maternal side negative   negative
Hu X et al negative   
Diaz SA et al     
Zamaniyan M et al PositiveNegativeNegative 
Hantoushzadeh S et al Positive   
Kirtsman M et alPositive Not testedPositivePositive
Table VII

Evidence for and against vertical transmission - Inconsistencies in the timing and repetition of RT-PCR makes it difficult to come to an inference

Study1st RT-PCRTime done2nd RT-PCRTime doneFor vertical transmissionAgainst vertical transmission
Yu N et al1 pos36 hours1 negWithin 2 weekCS, and baby was isolated for 14 daysPlacenta and cord blood neg.Contamination- baby showed mild SOBDon’t know exactly when baby became negative
Zeng L et al1posDay 2&41 negDay 6Cs, isolationCord blood and amniotic fluid neg.Positive in <5 days
 1posDay 2&41 negDay 6Cs isolationCord blood and amniotic fluid neg.Positive in <5 days
 1posDay 2&41 negDay 7If vag fluid contamination- why amniotic fluid neg?Cord blood and amniotic fluid neg.Prematurity complication.Vaginal fluid contamination(PPROM)Ex utero infec?
Wang S et al1 pos36 hrs1 negDay 15Long gap between 1st and 2nd RT-PCR- difficult to know if baby was positive within a week (5-7 days)Placenta and cord blood negBaby asymptomatic
Ferrazzi E et al2 posDay 12 posDay 3 Vaginal fluid contaminationLikely contamination. RT-PCR not repeated after 5 days.Babies were relatively asymptomatic.
 1 doubtfulFew hours after birth1 posDay 3 -do-
Alzamora MC et al1 pos16 hrs1 pos48 hrsCSDiabetesBaby positive <5 days.Had resp difficulty and needed ventilated but was premature at 33 weeks? Cause is prematurity.
Khan S et al2 pos24 hrsNot tested CSneonatal pneumoniaInsufficient information- pos at 24 hours and not repeated.
Nie R et al1 pos36 hrs1 negDay 4 Neg at D4Placenta cord blood negIsolated for 16 days?contamination
Carosso A et al1 pos0 hr1 neg37 hrs (on same swab) Vaginal contamination highly likely as same swab neg after 37 hours. Possibly low titres...
Hu X et al1 pos36 hrNot tested Positive >day 7IsolationCS-?verticalAmniotic fluid pos?ex-utero inf
Diaz SA et al1 negDay 671 posDay 8 High likelihood of ex-utero infection from Mum- Mum BF till D6 when baby showed symptoms and was tested.
Zamaniyan M et al1 neg0 hr1 pos24 hrs Amniotic fluid positive. If it was amniotic fluid contamination-should have been positive at birth as well. Cord blood was negative so unlikely vertical transmission?infection exutero?
Yu N et al1 pos36 hours1 negWithin 2 weekCS, and baby was isolated for 14 daysPlacenta and cord blood neg.Contamination- baby showed mild SOBDon’t know exactly when baby became negative
Zeng L et al1posDay 2&41 negDay 6Cs, isolationCord blood and amniotic fluid neg.Positive in <5 days
 1posDay 2&41 negDay 6Cs isolationCord blood and amniotic fluid neg.Positive in <5 days
 1posDay 2&41 negDay 7If vag fluid contamination- why amniotic fluid neg?Cord blood and amniotic fluid neg.Prematurity complication.Vaginal fluid contamination(PPROM)Ex utero infec?

*CS-Caesarean section; **PPROM-Prelabour premature rupture of membranes

Placenta, amniotic fluid, cord blood, breast milk, vaginal swab results. Evidence for and against vertical transmission - Inconsistencies in the timing and repetition of RT-PCR makes it difficult to come to an inference *CS-Caesarean section; **PPROM-Prelabour premature rupture of membranes Placental histology. *MTOP- Medical termination of pregnancy Given that the majority of pregnant women appear asymptomatic or have nonspecific symptoms (Table III), it was remarkable to have confirmation of SARS-CoV-2 placental damage, detection of SARS-CoV-2 RNA and the presence of whole viral particles on both maternal and fetal aspects of the placenta (Schoenmakers et al., 2020). Placental histological changes (Kirtsman et al., 2020; Shanes et al., 2020) provide important supporting tools to SARS-CoV-2 diagnostic testing when deciphering vertical transmission, especially considering that the majority of pregnant women appear asymptomatic although other infection routes such as through being born vaginally, breastfed or remaining with the infected mother (Walker et al., 2020). Several infected babies within 12 hours suggest an incubation period pre-existed the delivery to suggest vertical transmission (Table V). PCR positive SARS-CoV-2 tests in the amniotic fluid and infant provide important support for vertical transmission in SARS-CoV-2 infected pregnant women (Zamaniyan et al., 2020). A recent report outside our study cohort provides compelling data on vertical transmission and where the RT-PCR viral load was much higher in placental tissue than in amniotic fluid and maternal or neonatal blood (Vivanti et al., 2020) (Table VIII). Recent studies suggest SARS-CoV-2 vertical transmission, the associated chronic placental insufficiency, as well as miscarriage and fetal growth restriction (Gengler et al., 2020), while a systematic analysis shows a 3.3% intrapartum vertical transmission (Raschetti et al., 2020). Strong evidence of transplacental transmission in early pregnancy associated with hydrops fetalis and fetal demise due to SARS-CoV-2 is also reported (Shende et al., 2020).
Table III

Maternal symptoms and investigation.

StudySymptomsLymphopeniaThrombocytopeniaTransaminitisOthersRT-PCR (all positive)
Yu N et alFeverYesyes ↑ CRPCT-pneumoniaThroat swab positive, Sputum & nasopharyngeal postpartum neg
Zeng L et alFever, pneumonia    Nasopharyngeal
 Cough, pneumonia    Nasopharyngeal
 Pneumonia    Nasopharyngeal
Wang S et alFever, Pneumoniayes  ↑ CRPNeutrophiliaPharyngeal
Ferrazzi E et alPneumonia postpartum    Throat postpartum
Alzamora MC et almalaise, fatigue, fever, SOB   Metabolic acidosis, pancytopenia, raised CRPNasopharyngeal
Khan S et alFever, SOB, coughyes yes Pharyngeal
Nie R et alFever    Throat
Carosso A et almild fever, dry persistent cough    Nasopharyngeal swab positiverectal and stool swab postdelivery positive, vaginal swab postdelivery negative
Hu X et alFeveryes Yes Throat
Diaz SA et alPostpartum-fever, pneumonia    Test not specified
Zamaniyan M et alMyalgia, SOB, anorexia, nausea, non-productive cough, feveryes  ↑ CRPCT-pneumoniaNasal and throat
Hantoushzadeh S et alFever, coughyes  ↑ CRPCT-pneumoniaNasopharyngeal
Kirtsman M et almyalgia, decreased appetite, fatigue, dry cough, feveryes  Raised aPTTNasopharyngeal

*CRP- C-reactive protein; **CT-Computed tomography; ***SOB- Shortness of breath

Table V

Baby symptoms & treatment details..

StudySymptoms & signsTreatmentNNU admission (days)IsolationBreast feeding
Yu N et almild SOBnot ventilated14NR 
Zeng L et allethargy,fever, pneumoniaNR2NR 
 lethargy,fever, pneumonia vomitingNR4NR 
 resp distress, pneumonia, sepsis, coagulopathynon-invasive ventilation, anti-biotic, caffiene11NR 
Wang S et alClinically well, Ct chest showed changesNot ventilated, monitored13Yes 
Ferrazzi E et alNRNRNRNoYes
 GI symptoms. Had resp symptoms after 3 daysVentilated 24 hrs1YesNo
Alzamora MC et almild resp difficulty, sporadic coughVentilatedNRyesNo
Khan S et alNeonatal pneumoniaNRNRNR 
Nie R et alPulmonary infectionNo treatment required16Yes 
Carosso A et alAsymptomaticNot ventilatedNRYes 
Hu X et alAsymptomaticNRNRYes 
Diaz SA et alRespiratory distressCPAP x2hours5Yes (isolated on day 6 when mum positive)Yes
Zamaniyan M et alFeverNot ventilatedNRYes 
Hantoushzadeh S et alpneumonia, lymphopenia, prematurityVentilatedNRYes 
Kirtsman M et alhypoglycemia, feeding difficulty, hypothermianot ventilated, antibiotics glucose1YesYes

*NR- Not recorded ; ** CPAP- Continuous Positive Airway Pressure; ***CT- Computed tomography

Maternal symptoms and investigation. *CRP- C-reactive protein; **CT-Computed tomography; ***SOB- Shortness of breath Baby characteristics. *Caesarean section; **SVD-Spontaneous vaginal delivery; ***NR- Not recorded Baby symptoms & treatment details.. *NR- Not recorded ; ** CPAP- Continuous Positive Airway Pressure; ***CT- Computed tomography It seems that the timing of diagnostic tests and interpretation of results are not standardised in an obstetric medicine setting. From our data, it appears there is inconsistency in the tests, timing and repeatability of RT-PCR, adding to the uncertainty to reach credible inferences leading to likely false and inconsistent healthcare reassurances in relation to SARS-CoV-2 infectivity. Importantly, the incubation period and the timing of testing which could account for false-negative results appear to have been overlooked or not factored-in most studies in our cohort. Where repeat testing was performed this was not based on any critical scientific rationale. Despite a large volume of publications being added every month, there remains a fundamental absence of serial testing and over-reliance on a single test that underestimates the true positive cases as highlighted with our study. The most important question in reproductive and fetal medicine to be answered is whether there is a vertical transmission of SARS-CoV-2 virus from mother to baby and if there is an increased incidence of congenital malformations. This paper reveals that vertical transmission of SARS-CoV-2 based on diagnostic analyses is not accurately detected and it disregards the viral incubation period, placental pathologies and peripheral supporting data, thereby under-reporting mother to baby vertical transmission. In conclusion, the vast body of information generated during this SARS-CoV-2 pandemic may falsely reassure the public about the overall level of mother to baby viral transmission since serial testing after a negative test was not performed in over 80% of newborns. It is more important to amalgamate the diagnostic testing with good microscopic and histological analyses of the placenta for vertical transmission of SARS-CoV-2 to be assessed. The collective information of diagnostic analysis, incubation periods, placental and amniotic fluid data and increasingly positive cases suggest the argument for intrapartum vertical transmission is compelling and transmission from mother to baby cannot be dismissed. List of studies with babies positive for COVID 19.
Table II

Maternal characteristics.

StudyAgeParityGestationContact historyCo-morbiditiesOutcome
Yu N et al38G3P239+6NoHypothyroidismrecovered
Zeng L et al  40NR xNRrecovered
   40+4NRNRrecovered
   31+2NRNRrecovered
Wang S et al34 40YesHypothyroidismrecovered
Ferrazzi E et alMean-34.6  NRNRrecovered
Alzamora MC et al41G3P233YesPrev 2 CSDiabetesrecovered
Khan S et al29(24-34) 38(35+5 -41)YesNRrecovered
Nie R et al   NRNRrecovered
Carosso A et al28G2P137NRGDMrecovered
Hu X et al34 40YesNonerecovered
Diaz SA et al41 38+4YesHypothyroidism, IVF pregnancy, severe PETventilated
Zamaniyan M et al  32+2YeshypothyroidismDied
Hantoushzadeh S et al40-44G2P130+5NoSubclinical hypothyroidism, advanced maternal ageDied
Kirtsman M et al40G2P135+5NRfamilial neutropenia, GDM, recurrent bacterial infectionrecovered

Hypothyroidism and advanced maternal age were a common maternal morbidity. Elderly mums. For babies with positive results after D5 – 2 mums were critically ill and died after delivery. xNR- Not recorded.

Table IV

Baby characteristics.

StudyNo. of positive babiesGestationMode of deliveryApgar score @ 1,5,10 minBirth weight (gm)
Yu N et al139+6CS8-9,9-103250
Zeng L et al140CSNR3250
 140+4CSNR3360
 131+2CS3,4,51580
Wang S et al140CS8,93205
Ferrazzi E et al2 SVD>7 at 5 min3224
   SVDNR (Good condition)NR
Alzamora MC et al133CS6,82970
Khan S et al238(35+5 -41)CS9,103104 (mean)
Nie R et al1 CS8-10,9-10NR
Carosso A et al137SVD in neg pressure room9,103120
Hu X et al140CS8,93250
Diaz SA et al138+4CS7,92500
Zamaniyan M et al132+2CS8,92350
Hantoushzadeh S et al130+5CS9,102100
Kirtsman M et al135+5CS9,92930

*Caesarean section; **SVD-Spontaneous vaginal delivery; ***NR- Not recorded

Table IX

List of studies with babies positive for COVID 19.

StudyYearTitleLink
Yu N et al2020Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30176-6/fulltext
Zeng L et al2020Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China.https://jamanetwork.com/journals/jamapediatrics/fullarticle/2763787
Wang S et al2020A Case Report of Neonatal 2019 Coronavirus Disease in China.https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa225/5803274
Ferrazzi E et al2020Mode of Delivery and Clinical Findings in COVID-19 Infected Pregnant Women in Northern Italy.https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3562464
Alzamora MC et al2020Severe COVID-19 during Pregnancy and Possible Vertical Transmission.https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0040-1710050.pdf
Khan S et al2020Association of COVID-19 infection with pregnancy outcomes in healthcare workers and general women.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141623/pdf/main.pdf
Nie R et al2020Clinical features and the maternal and neonatal outcomes of pregnant women with coronavirus disease 2019.https://www.medrxiv.org/content/10.1101/2020.03.22.20041061v1.full.pdf
Carosso A et al2020Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 pregnant patients: is it time to think about it?https://www.ejog.org/article/S0301-2115(20)30202-5/pdf
Hu X et al2020Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia.https://journals.lww.com/greenjournal/Citation/9000/Severe_Acute_Respiratory_Syndrome_Coronavirus_2.97384.aspxDOI: 10.1097/AOG.0000000000003926
Diaz SA et al2020Neonatal first case of SARS-CoV-2 in Spain First case of neonatal infection due to SARS-CoV-2 in Spain.https://www.sciencedirect.com/science/article/pii/S1695403320301302?via%3Dihub
Zamaniyan M et al2020Preterm delivery in pregnant woman with critical COVID-19 pneumonia and vertical transmission.https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/pd.5713
Hantoushzadeh S et al2020Maternal Death Due to COVID-19 Disease.https://www.ajog.org/article/S0002-9378(20)30516-0/pdf
Schoenmakers S et al2020SARS-CoV-2 placental infection and inflammation leading to fetal distress and neonatal multi-organ failure in an asymptomatic woman.https://doi.org/10.1101/2020.06.08.20110437
Hosier H et al2020SARS–CoV-2 infection of the placentahttps://doi.org/10.1172/JCI139569
Shanes ED2020Placental pathology in COVID.https://doi.org/10.1093/ajcp/aqaa089
Kirtsman M et al2020Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection.doi: 10.1503/cmaj.200821
  32 in total

1.  SARS-CoV-2 infection of the placenta.

Authors:  Hillary Hosier; Shelli F Farhadian; Raffaella A Morotti; Uma Deshmukh; Alice Lu-Culligan; Katherine H Campbell; Yuki Yasumoto; Chantal Bf Vogels; Arnau Casanovas-Massana; Pavithra Vijayakumar; Bertie Geng; Camila D Odio; John Fournier; Anderson F Brito; Joseph R Fauver; Feimei Liu; Tara Alpert; Reshef Tal; Klara Szigeti-Buck; Sudhir Perincheri; Christopher Larsen; Aileen M Gariepy; Gabriela Aguilar; Kristen L Fardelmann; Malini Harigopal; Hugh S Taylor; Christian M Pettker; Anne L Wyllie; Charles Dela Cruz; Aaron M Ring; Nathan D Grubaugh; Albert I Ko; Tamas L Horvath; Akiko Iwasaki; Uma M Reddy; Heather S Lipkind
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

2.  Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review.

Authors:  Benjamin J F Huntley; Erin S Huntley; Daniele Di Mascio; Tracy Chen; Vincenzo Berghella; Suneet P Chauhan
Journal:  Obstet Gynecol       Date:  2020-08       Impact factor: 7.661

3.  Transplacental transmission of SARS-CoV-2 infection.

Authors:  Alexandre J Vivanti; Christelle Vauloup-Fellous; Sophie Prevot; Veronique Zupan; Cecile Suffee; Jeremy Do Cao; Alexandra Benachi; Daniele De Luca
Journal:  Nat Commun       Date:  2020-07-14       Impact factor: 14.919

4.  Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring.

Authors:  Shu-Yuan Xiao; Yingjie Wu; Huan Liu
Journal:  J Med Virol       Date:  2020-02-17       Impact factor: 2.327

5.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

6.  Understanding Antibody Testing for COVID-19.

Authors:  David Jacofsky; Emilia M Jacofsky; Marc Jacofsky
Journal:  J Arthroplasty       Date:  2020-04-27       Impact factor: 4.757

7.  A novel coronavirus outbreak of global health concern.

Authors:  Chen Wang; Peter W Horby; Frederick G Hayden; George F Gao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Authors:  Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten
Journal:  Euro Surveill       Date:  2020-01

9.  SARS-CoV-2 ACE-receptor detection in the placenta throughout pregnancy.

Authors:  Carole Gengler; Estelle Dubruc; Guillaume Favre; Gilbert Greub; Laurence de Leval; David Baud
Journal:  Clin Microbiol Infect       Date:  2020-10-03       Impact factor: 8.067

10.  Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis.

Authors:  John Allotey; Elena Stallings; Mercedes Bonet; Magnus Yap; Shaunak Chatterjee; Tania Kew; Luke Debenham; Anna Clavé Llavall; Anushka Dixit; Dengyi Zhou; Rishab Balaji; Siang Ing Lee; Xiu Qiu; Mingyang Yuan; Dyuti Coomar; Jameela Sheikh; Heidi Lawson; Kehkashan Ansari; Madelon van Wely; Elizabeth van Leeuwen; Elena Kostova; Heinke Kunst; Asma Khalil; Simon Tiberi; Vanessa Brizuela; Nathalie Broutet; Edna Kara; Caron Rahn Kim; Anna Thorson; Olufemi T Oladapo; Lynne Mofenson; Javier Zamora; Shakila Thangaratinam
Journal:  BMJ       Date:  2020-09-01
View more
  6 in total

Review 1.  COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns.

Authors:  Mohamed Joma; Claire-Maelle Fovet; Nabila Seddiki; Pierre Gressens; Mireille Laforge
Journal:  Vaccines (Basel)       Date:  2021-04-15

2.  Secondary Hemophagocytic Lymphohistiocytosis in a Neonate with SARS-CoV-2 Infection.

Authors:  Hasan Zuhair El-Isa; Osama As'ad Khader; Mustafa Khader; Bahaa Abed Ashour; Muayad Imad Azzam; Eman Farouk Badran
Journal:  Am J Case Rep       Date:  2022-01-28

Review 3.  Coronavirus Disease 2019 Infection in Newborns.

Authors:  Jeffrey M Perlman; Christine Salvatore
Journal:  Clin Perinatol       Date:  2021-11-09       Impact factor: 3.430

4.  SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy.

Authors:  Jenny C Jin; Aparna Ananthanarayanan; Julia A Brown; Stephanie L Rager; Yaron Bram; Katherine Z Sanidad; Mohammed Amir; Rebecca N Baergen; Heidi Stuhlmann; Robert E Schwartz; Jeffrey M Perlman; Melody Y Zeng
Journal:  Pediatr Res       Date:  2022-08-19       Impact factor: 3.953

5.  Plasma Lipidomic and Metabolomic Profiling after Birth in Neonates Born to SARS-CoV-19 Infected and Non-Infected Mothers at Delivery: Preliminary Results.

Authors:  Aggeliki Kontou; Christina Virgiliou; Thomai Mouskeftara; Olga Begou; Thomas Meikopoulos; Agathi Thomaidou; Eleni Agakidou; Helen Gika; Georgios Theodoridis; Kosmas Sarafidis
Journal:  Metabolites       Date:  2021-11-30

6.  Effects of the early phase of the COVID-19 pandemic on natural and ART-mediated birth rates in Lombardy Region, Northern Italy.

Authors:  Edgardo Somigliana; Giovanna Esposito; Paola Viganò; Matteo Franchi; Giovanni Corrao; Fabio Parazzini
Journal:  Reprod Biomed Online       Date:  2021-07-30       Impact factor: 3.828

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.